Objectives. The arachidonate 5-lipoxygenase activating protein (ALOX5AP) regulates synthesis of leukotrienes (LTs), which are important mediators of inflammation and connective tissue remodelling. The aim of this study was to evaluate if single nucleotide polymorphisms (SNPs) of ALOX5AP confer risk of SSc and/ or SSc-related organ involvement.
Introduction
SSc (scleroderma) is an autoimmune disease characterized by widespread vascular injury and profound fibrosis of the skin and internal organs. Involvement of internal organs accounts for the high morbidity and mortality in SSc. In particular, pulmonary complications such as interstitial lung disease (ILD) and pulmonary hypertension (PH) are at present the main causes of disease-related deaths in SSc patients [1, 2] .
SSc shows a complex aetiology in which both environmental and genetic factors seem to influence the onset and outcome of the disease [3, 4] . Activation of the immune system, chronic inflammation, vascular injury and increased synthesis of connective tissue components are believed to play key roles in the pathogenesis of SSc [3] . However, the exact mechanisms responsible for development and progression of the disease are not fully understood. It is believed that a better understanding of the pathogenesis of SSc would allow development of effective and well-tolerated therapies [5] .
Leukotrienes (LTs) are a family of lipid mediators derived from arachidonic acid through the action of 5-lipoxygenese (5-LOX) and include LT A4 (LTA4), a short-living intermediate product that is rapidly converted to LT B4 (LTB4) or cysteinyl LTs (cysLTs), which include LTs C4 (LTC4), D4 (LTD4) and E4 (LTE4) [6] . LTs exert a broad range of biological activities, generally of pro-inflammatory and pro-fibrotic properties [6] . LTs have been implicated in the pathogenesis of many inflammatory diseases, including RA, asthma and atherosclerosis as well as conditions associated with connective tissue remodelling such as pulmonary or liver fibrosis [710] .
It has already been shown that synthesis of LTs is increased in the lungs of patients with SSc-related ILD (SSc-ILD) and in the peripheral blood mononuclear cells (PBMCs) derived from SSc patients [1114] . However, the mechanisms underlying overproduction of LTs in SSc have not been clarified.
Arachidonate 5-lipoxygenase activating protein (ALOX5AP), also known as 5-lipoxygenese activating protein (FLAP), is a membrane-bound protein that presents arachidonic acid to 5-LOX, and in this way regulates the amount of synthesized LTs [reviewed in more detail in refs 15, 16] . It has recently been shown that several single nucleotide polymorphisms (SNPs) of the ALOX5AP gene are associated with increased risk of inflammatory disease, such as asthma and atherosclerosis [1721] . However, no study has investigated associations between ALOX5AP polymorphisms and SSc.
We hypothesized that SNPs of ALOX5AP might be associated with the risk of SSc and/or its major organ complications. To address this hypothesis, seven SNPs that had been shown to be linked to higher risk of other inflammatory conditions were investigated in a cohort of SSc patients from the European Scleroderma Trials and Research (EUSTAR) group.
Methods
Patients and controls DNA samples from 977 patients with SSc and 558 sexand age-matched healthy controls were provided from European centres collaborating within the EUSTAR group. All patients and controls selected for the study were of European Caucasian origin and all SSc patients fulfilled the ACR classification criteria for SSc [22] . SSc patients were classified as having dcSSc or lcSSc based on criteria by LeRoy et al. [23] .
The presence of SSc-ILD, PH, scleroderma renal crisis (SRC), digital ulcers (DUs), ANA, ACA and anti-topo I antibodies was evaluated according to the guidelines of the EUSTAR database, as described previously [24, 25] . In brief, SSc-ILD was diagnosed based on typical findings on high-resolution CT (HRCT) of the lungs and was considered clinically significant when restrictive ventilatory defect, defined as a forced vital capacity (FVC) <70% of predictive value, was found in pulmonary function tests. The presence of PH was defined as pulmonary artery systolic pressure >45 mmHg, which was show to have 95% specificity vs right heart catheterization, which is considered a gold standard for diagnosis of PH [26] . SRC was defined as new renal insufficiency with or without arterial hypertension that could not be explained by reasons other than SSc. DUs were defined as painful areas of loss of tissue distal to the PIP digital crease. Approval was obtained from the Bioethics Committee of the Medical University of Bialystok and written informed consent was given by all participants. The clinical characteristics of the patients are presented in Table 1. www.rheumatology.oxfordjournals.org
Genotyping
Seven SNPs of ALOX5AP (rs17222814, rs17216473, rs10507391, rs4769874, rs9551963, rs9315050 and rs7222842) were selected based on their ability to tag haplotypes that were previously shown to be associated with myocardial infarction (ischemic heart disease/atherosclerosis) and production of LTs [1721] . The locations of the investigated SNPs within the ALOX5AP gene, according to the 1000 Genomes phase III study, are shown in supplementary Fig. 1 , available at Rheumatology Online and given in Table 2 [27] .
The allele-specific probes and primers were obtained from Applied Biosystems (AB) for the TaqMan colorimetric microtitre plate-based real-time PCR assay. Each individual assay was performed using 20 ng of genomic DNA and two allele-specific probes, one labelled with VIC and the other with FAM. The reaction was performed in a 384-well plate in a final volume of 10 ml/reaction using an ABI 7900HT Sequence Detection System (Applied Biosystems, Carlsbad, CA, USA) with the following thermal cycle profile: initial denaturation 10 min at 95 C, then 40 cycles of 15 s each at 95 C and 60 s at 60 C. The scoring of the genotypes was performed using SDS 7.1 software provided by AB. The results of genotyping were confirmed with direct sequencing for all SNPs in randomly selected samples.
PBMC cultures and measurements of LTs in supernatants
In a subset of 22 SSc patients, LTB4 and cysLTs were measured in the supernatants of the PBMCs. To avoid modification of the activity of leucocytes by immunosuppressive or NSAID drugs, only patients who had not taken any immunosuppressive therapies or NSAIDs or in whom immunosuppressive therapies and NSAIDs had been stopped at least 6 months or 1 month, respectively, before blood collection were considered eligible.
Heparin anti-coagulated peripheral blood samples were obtained from the cubical vein in the morning after the patient had fasted for at least 10 h. PBMCs were isolated from the whole blood using density gradient centrifugation on Histopaque. The isolated PBMCs were resuspended in RPMI medium supplemented with 5% foetal calf serum at a density of 10 5 cells/ml and cultured at 37 C under 5% CO 2 for 24 h. After that, the cells were washed and exposed to inophore A23187 (1 mmol/l) for 15 min. Subsequently the cell suspensions were centrifuged and supernatants were collected and frozen at À80 C until measurements were made. Evaluation of LT concentrations in the supernatants was performed using commercially available enzyme immunoassay kits (Cayman Chemicals, Ann Arbor, MI, USA).
Statistical analysis
Haploview software (Broad Institute, Cambridge, MA, USA) was used to assess linkage disequilibrium between SNPs and haplotype analysis. For the assessment of between-group comparisons the chi-square, Fisher's and MannWhitney tests were used, as appropriate. Bonferroni correction was applied to correct for multiple comparisons when comparing patients with SSc and control subjects (10 phenotypic subsets). In addition, to assess the potential influence of the geographical origin of samples on association between specific SNPs and the presence of SSc or SSc-ILD, appropriate multivariate logistic regression models were created. In these models, the geographical origin of the samples was defined as the average latitude of the country from which the DNA samples originated, based on data from the MaxMind Dev Documentation website [28] .
The differences were considered significant at P-values <0.05.
All results are expressed as mean (S.D.) or odds ratio (OR) and 95% CI unless stated otherwise.
Results

Patient characteristics
A total of 977 SSc patients were included. Detailed clinical characteristics of SSc patients are presented in Table 1 . Among 913 for whom appropriate clinical information about skin disease was available, 284 (31%) had dcSSc while the remaining 629 (69%) had lcSSc according to Medsger and LeRoy [23] . ANA were present in >90%, anti-topo I antibodies in one-fourth and ACA in one-third of SSc patients for whom appropriate information was given. Scleroderma-related ILD, defined based on HRCT findings, was present in 440 (52.4%) of 839 SSc patients and restrictive ventilatory defect, defined as FVC <70% of predicted value, was present in 144 (16.5%) of 872 SSc patients with appropriate information available.
PH and DUs were present in $10% and 35% of SSc patients, respectively. Information concerning SRC was reported in 403 SSc patients, of whom only 10 (2.5%) developed this complication. These numbers are consistent with previously reported characteristics of SSc patients from the database of the EUSTAR group [24, 25] .
Association between ALOX5AP SNPs and SSc and SSc-related organ involvement
All investigated polymorphisms met the HardyWeinberg equilibrium ( Table 2) . Frequencies of minor alleles of all investigated SNPs of ALOX5AP for SSc patients and control subjects are given in Table 2 . Associations between ALOX5AP polymorphisms and SSc and SSc-related organ involvement are shown in Tables 3 and 4 . A significant association was found between rs10507391 polymorphism of the ALOX5AP gene and SSc. The A allele of ALOX5AP rs10507391 was present in 34% of SSc patients as compared with 29% of controls (P = 0.0043). The presence of the A allele was associated with a higher risk of SSc [OR 1.27 (95% CI 1.07, 1.50), P < 0.05]. Comparison with the control group revealed associations between rs10507391 polymorphism and several clinical and immunological features of SSc, including both diffuse and limited subsets of the disease, the presence of SSc-ILD, restrictive ventilator defect, PH, DUs, ANA and anti-topo I antibodies. However, only associations of the rs10507391 polymorphism with SSc, SSc-ILD and restrictive defect remained significant when corrected for multiple testing (P < 0.05 after Bonferroni correction) ( Table 3) .
We have not investigated associations between the SNPs of ALOX5AP and SRC because of the small number of patients with SRC. To further investigate associations between the rs10507391 polymorphism and the phenotype of SSc patients we performed analyses within the SSc group. We found a strong association between the rs10507391 polymorphism and the presence of SSc-ILD in HRCT [OR 1.45 (95% CI 1.17, 1.79), P < 0.001] and with restrictive ventilatory defect [OR 1.51 (95% CI 1.16, 1.97), P < 0.01] in SSc patients ( Table 4) .
The presence of the A allele of this polymorphism (AA or AT genotype) was linked to a significantly higher risk of No significant associations could be found between the remaining SNPs of ALOX5AP and the presence of SSc or SSc-related internal organ involvement (Table 3) . No significant associations could be found between different haplotypes of ALOX5AP and the presence of SSc or SSc phenotypes.
Influence of geographical origin of DNA samples on the association between the rs10507391 polymorphism of ALOX5AP and SSc and SSc-ILD The results of the 1000 Genomes phase III study indicate that the frequency of the A allele of the rs10507391 polymorphism of ALOX5AP, which in our present study was significantly associated with SSc and SSc-ILD, shows a clear northsouth gradient across Europe [27] . Since the DNA samples used in our study originated from six different European countries (Sweden, The Netherlands, Poland, Germany, France and Italy) we aimed to evaluate the potential influence of geographical origin of the DNA samples on associations between the presence of the A allele of the rs10507391 polymorphism and SSc, SSc-ILD on HRCT and restrictive ventilator defect. To address this question, multivariate logistic regression models including the average latitude of the country of DNA samples origin as one of potential predictors were created. The results of these models are shown in supplementary Tables 13, available at Rheumatology Online.
Both the presence of the A allele of the rs10507391 polymorphism (AA or AT genotype) and the geographical origin of the samples (the average latitude of the country of DNA origin) were significantly associated with the risk of SSc (see supplementary Table 1 , available at Rheumatology Online). The OR for SSc in the carriers of According to the 1000 Genomes phase III study [27] . MAF: minor allele frequency.
www.rheumatology.oxfordjournals.org
TABLE 3
Associations of ALOX5AP polymorphisms with SSc and SSc-related organ involvement or autoantibodies Values in bold are statistically significant. Data are presented as odds ratio (95% CI) (vs control group), P unadjusted. *P-value adjusted for multiple comparisons using Bonferroni correction.
the A allele of the rs10507391 polymorphism in this model was 1.31 (95% CI 1.05, 1.63), indicating that the presence of the A allele increases the risk of SSc by >30%. The OR for the geographical origin of samples was 1.07 (95% CI 1.05, 1.09), indicating that the risk of SSc increases 7% for every degree of latitude from the south to the north of Europe.
Unlike for the presence of SSc, the geographical origin of the samples had no significant effect on the presence of SSc-ILD on HRCT or restrictive ventilatory defect in SSc patients (supplementary Tables 2 and 3 , available at Rheumatology Online). In the multivariate logistic regression models the presence of SSc-ILD on HRCT or restrictive ventilatory defect were significantly associated only with the presence of the A allele of the rs10507391 polymorphism (supplementary Tables 2 and 3 , available at Rheumatology Online). In the carriers of the A allele of the rs10507391 polymorphism, the OR for SSc-ILD on HRCT was 1.46 (95% CI 1.10, 1.93) and for restrictive ventilatory defect was 1.74 (95% CI 1.19, 2.56) after adjustment for the geographical origin of DNA samples.
Relationships between the rs10507931 polymorphism of ALOX5AP and LT synthesis by PBMCs in SSc patients
The synthesis of LTs by ionophore-stimulated PBMCs was evaluated in 22 patients with SSc. This group consisted of 12 TT homozygotes, 8 AT heterozygotes and 2 AA homozygotes of the rs10507391 polymorphism of ALOX5AP (Figs 1 and 2 ). Because the number of patients with the AA variant of the rs10507931 polymorphism included in this experiment was too low for statistical analysis, those patients were evaluated together with the AT heterozygotes.
PBMCs from SSc carriers of the rs10507391 allele A (n = 10) synthesized greater amounts of cysLTs [mean 438 pg/ml/10 5 cells (S.D. 154)] as compared with PBMCs from SSc patients with the rs10507391 TT genotype [n = 12; 236 pg/ml/10 5 cells (S.D. 95), P < 0.05] (Fig. 1) .
No significant differences could be found in the synthesis of LTB4 between the two groups [774 pg/ml/10 5 cells (S.D.
351) vs 526 (S.D. 384), P = 0.1] (Fig. 2) .
Discussion
In the present study we showed, for the first time, an association between genetic variants of the ALOX5AP gene and the risk of SSc and SSc-ILD. In our study the A allele of the rs10507391 (also known as SG13S114) polymorphism confers a greater risk of SSc-ILD. Moreover, we showed that the presence of the risk allele of this polymorphism (the allele A of rs10507391) is associated with greater synthesis of cysLTs by PBMCs from patients with SSc as compared with scleroderma patients who do not carry this allele. This is in agreement with the results of Domingues-Montanari et al. [19] , who showed that the presence of the A allele of rs10507391 is associated with greater expression of ALOX5AP mRNA in peripheral blood leucocytes from healthy subjects. In the study by Domingues-Montanari et al. [19] , the level of expression of ALOX5AP mRNA correlated with the number of A alleles of the rs10507391 polymorphism, with the greatest amounts found in AA homozygotes, intermediate in AT heterozygotes and lowest in TT homozygotes of rs10507391 carriers.
To the best of our knowledge there have been no studies investigating relationships between ALOX5AP polymorphisms and ILD. Interestingly, in the study of Holloway et al. [21] , the presence of the A allele of the rs10507391 polymorphism was associated with a greater risk of asthma in Caucasian families, indicating a possible link between this polymorphism and lung pathology. Moreover, the presence of the A allele of the rs10507391 polymorphism was associated with impaired lung function, greater hypersensitivity and more severe atopy. Although the presence of the rs10507391 polymorphism showed no significant association with the risk of asthma in Mexicans and had a protective effect against asthma in the population of Puerto Rico, the presence of the rs10507391 polymorphism was associated with worse lung function in those populations [29] . Interestingly, in our present study the rs10507391 polymorphism showed a significant association not only with the presence of SSc-ILD in HRCT, which is a very sensitive method that detects clinically insignificant lung disease, but also with restrictive ventilatory defect, which is known to be associated with a higher risk of progression of SSc-ILD and death in SSc patients [30, 31] .
Our present findings indicate that LT synthesis might play a role in the pathogenesis of SSc-ILD and are in line with the results of previous research from our group and others showing increased synthesis of LTs in patients with SSc-ILD. Indeed, we have previously shown that concentrations of LTB4 and cysLTLTE4 are significantly increased in the lungs of patients with SSc-ILD as www.rheumatology.oxfordjournals.org compared with SSc patients without pulmonary fibrosis and healthy controls [11, 12] . We have also shown that PBMCs from patients with SSc in vitro synthesized greater amounts of LTB4 compared with PBMCs from healthy subjects [14] . Interestingly, although baseline synthesis of cysLTs by PBMCs in our study did not differ significantly between SSc patients and healthy controls, greater baseline synthesis of cysLTs was associated with worse clinical prognosis (higher risk of death or progression of SSc-related internal organ complication) in patients with scleroderma [14] . Understanding the exact role of LTs in the pathogenesis of SSc-ILD requires further studies. However, it could be speculated that genetically determined overproduction of LTs, spontaneously and in response to injury, can contribute to the development of SSc-ILD through direct and/or indirect promotion of fibrosis, which is considered the main and irreversible component of the pathogenesis of SSc-ILD. The potential contribution of LTs in the pathogenesis of SSc-ILD is discussed in detail in ChwieskoMinarowska et al. [9] and Kowal-Bielecka et al. [10] . Involvement of LTs in the development of SSc-ILD is further underlined by the results of experimental studies showing that blockade of LT pathways might prevent or diminish the development of experimental pulmonary fibrosis [3236] .
Associations between ALOX5AP polymorphisms and the presence of SSc-ILD not only underline the role of the LT pathway in the pathogenesis of this complication, but might provide the rationale for developing
FIG. 1 Production of cysLTs in SSc patients with different genotypes of the rs10507391 polymorphism
The concentration of cysLTs was measured in the supernatants of the PBMCs stimulated with ionophore A23187.
FIG. 2 Production of LTB4 in SSc patients with different genotypes of the rs10507391 polymorphism
The concentration of LTB4 was measured in the supernatants of the PBMCs stimulated with ionophore A23187. genotype-specific therapy or prevention for SSc-related lung involvement. This hypothesis appears particularly interesting since inhibitors of LT synthesis or LT receptor antagonists have been approved for the treatment of allergic diseases such as asthma. However, inhibition of 5-LOX, which is a target of current LT synthesis inhibitors, leads to inhibition of the synthesis of anti-inflammatory and anti-fibrotic lipoxins, which are synthesized due to cooperation of 5-LOX and 15-LOX. Inhibition of ALOX5AP appears therefore to be a more specific way to inhibit the LT pathway without diminishing the synthesis of lipoxins. Interestingly, ALOX5AP inhibitors have been tested in humans and show a good safety profile and anti-inflammatory effects [3740] .
In conclusion, the results of our study indicate that the genetic variants of ALOX5AP are associated with the presence of SSc-ILD and worse lung function in SSc patients, supporting the role of 5-LOX/ALOX5AP metabolites in the pathogenesis of SSc-related pulmonary fibrosis. Moreover, our results might raise the possibility of developing genotype-specific therapy for SSc-related lung involvement. A prospective study designed to evaluate the role of the rs10507391 ALOX5AP polymorphism as a prognostic factor for a poor outcome of SSc should answer this question. 
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